Mylan's Aflibercept Biosimilar Gets Green Light For Trials In India

 
• By Anju Ghangurde

Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.

Green
Mylan's Biosimlar Rival To Eylea Gets Go Ahead For Phase III • Source: Shutterstock

More from Biosimilars

More from Products